- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06671886
NAFLD 임상 치료 경로 (NCCP)
VA 1차 진료에서 NAFLD 임상 치료 경로의 효과 테스트
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatment of NAFLD. This clinical trial will test the benefit of this NCCP intervention against usual care in increasing the rates of NAFLD diagnosis as well as referral to and enrollment in appropriate treatment. The study will also identify barriers and promotors of future NCCP implementation.
연구 개요
상세 설명
Background: In the United States, non-alcoholic fatty liver disease (NAFLD) affects 25-30% of adults and has become a leading cause of chronic liver disease including cirrhosis and liver cancer. The burden of NAFLD and its complications among patients in the Department of Veterans Affairs (VA) is increasing. Most complications occur among patients with advanced hepatic fibrosis. Treatment (e.g., weight loss) improves patients' outcomes.
Significance: The investigator's data indicate that most VA patients with NAFLD are undiagnosed and untreated. There is an urgent need to address this major gap in care. Most people with NAFLD are seen in primary care settings. The NAFLD Clinical Care Pathway (NCCP) is a multistep, algorithmic process that entails identification of patients at risk through an e-trigger (Step 1), targeted history and lab testing (Step 2), noninvasive testing for hepatic fibrosis using FIB-4 (Step 3), elective additional fibrosis testing with Fibroscan for those with indeterminate FIB-4 (Step 4), and subsequent recommended management. The NCCP has face and content validity based on consensus of multiple stakeholders including VA clinicians, and high efficacy in the investigator's preliminary data. The investigators propose to adapt the multicomponent NCCP intervention for use in VA primary care and prospectively test its effectiveness for identification and severity stratification of patients with NAFLD. The investigator's approach is consistent with VA strategic priorities to implement a more "Veteran-centered" approach that improves access to care.
Innovation & Impact: This is the first study to examine the effectiveness of any NAFLD clinical care pathway in a VA primary care practice. The design is a cluster-randomized controlled trial with randomization at the level of Patient Aligned Care Teams (PACTs) in primary care, and a state-of-the-art technique to diagnose NAFLD and stage the severity of hepatic fibrosis. The investigator's formative and summative evaluation will provide key information about the feasibility, acceptability and determinants of implementation. The NCCP intervention is a paradigm shift in NAFLD care from haphazard and sporadic care into a systematic, equitable, and evidence-based approach.
Specific Aims: Aim 1. Conduct a formative evaluation to assess feasibility and acceptability of the NCCP among patients and providers; adapt the NCCP for prospective testing based on feedback. Aim 2. Examine the effectiveness of the NCCP intervention compared to usual care in improving NAFLD care processes and patient outcomes. Aim 3. Conduct a summative evaluation to identify patient and provider characteristics associated with effectiveness of NCCP and to assess future implementation. The investigator's hypothesis is that NCCP when adapted to Patient Aligned Care Teams (PACTs) in VA primary care considerably increases the identification of patients with NAFLD and those with high-risk NAFLD, and results in an increase in guideline-concordant management.
Methodology: The study will be conducted in primary care settings in a single large VA Medical Center. The investigators will conduct patient interviews and focus groups with PACTs to inform adaption of the NCCP. The investigators will then conduct a cluster-randomized trial of 16 PACTs in primary care to compare the effectiveness of NCCP to usual care in improving NAFLD care, with PACTs as unit of randomization and patients as the unit of analysis. The multicomponent intervention includes an e-trigger to identify patients eligible for NAFLD screening and calculate fibrosis scores, a structured provider education on NAFLD management and treatment recommendations, and coordination by an inter-professional team. The primary outcome will be a composite binary variable consisting of NAFLD diagnosis and risk stratification. Secondary outcomes include referral to a weight loss program, referral of patients with advanced fibrosis to hepatology specialty care, and enrollment among those referred to weight loss and hepatology specialty care. Summative evaluation will inform future implementation.
Next Steps/Implementation: The investigators study will provide information needed to support future projects to implement the NCCP in VA primary care settings. The study will also lay the foundation for a subsequent project to examine the adopted intervention's effect on weight loss and NAFLD biomarkers in patients with high-risk NAFLD.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Hashem B El-Serag, MD MPH
- 전화번호: (713) 794-8640
- 이메일: Hashem.El-Serag@va.gov
연구 연락처 백업
- 이름: Kyler Godwin, PhD MPH BS
- 전화번호: (713) 440-4672
- 이메일: kyler.godwin@va.gov
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030-4211
- 모병
- Michael E. DeBakey VA Medical Center, Houston, TX
-
연락하다:
- Hashem B El-Serag, MD MPH
- 전화번호: (713) 794-8640
- 이메일: Hashem.El-Serag@va.gov
-
연락하다:
- Kyler Godwin, PhD MPH BS
- 전화번호: (713) 440-4672
- 이메일: kyler.godwin@va.gov
-
수석 연구원:
- Hashem B. El-Serag, MD MPH
-
부수사관:
- Kyler Godwin, PhD MPH BS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center
Exclusion Criteria:
-
The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization
-
PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination
-
PACTs meeting the following criteria will be excluded from randomization in Aim 2:
- PACTs who do not treat NAFLD
- PACTs not located at the main hospital
- PACTs with less than 100 visits within 3 months
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: E-trigger
The NCCP Intervention is made up of multiple components. The investigators will start by applying the e-trigger and assessing the FIB-4 score, and then will train and educate PACT personnel on managing patients with positive triggers, including making treatment recommendations in collaboration with an inter-professional team. The e-trigger will be generated every three months. |
The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned. |
|
간섭 없음: Usual care
The control group will receive no additional training or education. PACTs will provide usual care. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
NAFLD Diagnosis and risk stratification
기간: Baseline, 6 months
|
The investigators will use chart reviews to extract unstructured data regarding the primary outcome measure: existence of electronic health record (EHR) progress note documenting a new NAFLD diagnosis AND complete risk stratification of NAFLD (i.e., fibrosis). The investigators will use our validated process to guide uniform abstraction and classification. |
Baseline, 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Fibroscan Test
기간: Baseline, 6 & 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient had a fibroscan test. |
Baseline, 6 & 12 months
|
|
Referral to hepatology
기간: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to a hepatology clinic. |
Baseline, 6 and 12 months
|
|
Hepatology Clinic Visit
기간: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was seen in a hepatology clinic. |
Baseline, 6 and 12 months
|
|
NAFLD discussion
기간: 6 and 12 months
|
The investigators will extract from the patient chart if the provider documented a discussion about NAFLD with the patient. |
6 and 12 months
|
|
Referral to weight loss services
기간: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
|
Enrollment in weight loss services
기간: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Hashem B. El-Serag, MD MPH, Michael E. DeBakey VA Medical Center, Houston, TX
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IIR 22-071
- 5I01HX003655-03 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The investigators will not share data at the individual level, only in aggregate. No data will leave the VA.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .